GlaxoSmithkline Consumer’s Q2FY13 net jumps by 30%

Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) | Consumer Food | FMCG | BSE: 500676 | NSE: GSKCONS

01 Aug 2012 Evaluate

GlaxoSmithkline Consumer Healthcare has reported results for the second quarter ended June 30, 2012.

The company’s net profit jumped by 29.27% at Rs 106.60 crore for the quarter under review as compared to Rs 82.46 crore for the quarter ended June 30, 2011. Total income of the company has increased by 14.16% to Rs 786.96 crore for the Q2FY13 from Rs 689.35 crore for the similar quarter of the previous year.

GlaxoSmithkline Consumer Healthcare’s core business is manufacturing of health drinks under the brand Horlicks. It exports products to countries like Bangladesh, Myanmar, Sri Lanka, Middle East, Fiji, Mauritius, Nepal, Bhutan and many more.

Peers

Company Name	CMP
Nestle India	1344.55
Varun Beverages	431.05
Britannia Industries	4859.45
LT Foods	407.10
Hatsun Agro Product	1101.50
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.